described the use of in vivo dual-adeno-associated virus (AAV)-delivered CRISPR gene editing components to repair the OTC gene in the sparse fur ash (spfash) rodent model of OTC deficiency. The gene discussed is OTC; the disease is ornithine carbamoyltransferase deficiency.